(Q40041737)

16 September 2017

Nilotinib for the treatment of chronic myeloid leukemia (English)

1 reference

16 September 2017

chronic myeloid leukemia

0 references

author name string

Theo Daniel Kim

series ordinal

1

1 reference

PubMed ID

21083005

16 September 2017

Bernd Dörken

series ordinal

2

1 reference

PubMed ID

21083005

16 September 2017

Philipp le Coutre

series ordinal

3

1 reference

16 September 2017

1 October 2008

1 reference

Expert Review of Hematology

16 September 2017

1 reference

16 September 2017

1

1 reference

16 September 2017

1

1 reference

16 September 2017

29-39

1 reference

Chronic myeloid leukaemia

16 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Part II: management of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Flying under the radar: the new wave of BCR-ABL inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Imatinib therapy for chronic myeloid leukemia: where do we go now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.1.1.29

21 January 2018

Identifiers

DOI

10.1586/17474086.1.1.29

1 reference

16 September 2017

1 reference

PubMed ID

21083005